Antje Belau

1.5k total citations
42 papers, 678 citations indexed

About

Antje Belau is a scholar working on Reproductive Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Antje Belau has authored 42 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Reproductive Medicine, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Oncology. Recurrent topics in Antje Belau's work include Ovarian cancer diagnosis and treatment (28 papers), Endometrial and Cervical Cancer Treatments (9 papers) and Intraperitoneal and Appendiceal Malignancies (7 papers). Antje Belau is often cited by papers focused on Ovarian cancer diagnosis and treatment (28 papers), Endometrial and Cervical Cancer Treatments (9 papers) and Intraperitoneal and Appendiceal Malignancies (7 papers). Antje Belau collaborates with scholars based in Germany, United States and Austria. Antje Belau's co-authors include Sibylle Loibl, Carsten Denkert, Silvia Darb‐Esfahani, Jalid Sehouli, Hans Tesch, Jens Huober, Keyur Mehta, Dirk M. Zahm, Maik Hauschild and B. Högel and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Antje Belau

40 papers receiving 655 citations

Peers

Countries citing papers authored by Antje Belau

Since Specialization

Citations

This map shows the geographic impact of Antje Belau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antje Belau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antje Belau more than expected).

Fields of papers citing papers by Antje Belau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antje Belau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antje Belau. The network helps show where Antje Belau may publish in the future.

Co-authorship network of co-authors of Antje Belau

This figure shows the co-authorship network connecting the top 25 collaborators of Antje Belau. A scholar is included among the top collaborators of Antje Belau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antje Belau. Antje Belau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial 2023 ·European Journal of Cancer ·Marcus Schmidt, Ulrike Nitz, Toralf Reimer, Sabine Schmatloch, Heiko Graf, Marianne Just, Elmar Stickeler, Michael Untch, Ingo B. Runnebaum, Antje Belau, Jens Huober, Christian Jackisch, Manfred Hofmann, (unknown), Valentina Nekljudova, Sibylle Loibl	1
2	Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ) 2023 ·Journal of Cancer Research and Clinical Oncology ·Radoslav Chekerov, (unknown), Klaus Pietzner, Ulrich Canzler, Pauline Wimberger, Hans‐Georg Strauß, Sven� Mahner, Linn Woelber, Nikolaus de Gregorio, (unknown), (unknown), Tanja Neunhoeffer, Antje Belau, Alexander Mustea, (unknown), Elena Ioana Braicu, Rolf Richter, Jalid Sehouli, (unknown)	2
3	The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis 2023 ·Geburtshilfe und Frauenheilkunde ·Naiba Nabieva, (unknown), (unknown), (unknown), (unknown), Antje Belau, Steffi Busch, (unknown), Georg Heinrich, (unknown), Susanne Markmann, (unknown), Gülten Oskay-Özcelik, (unknown), (unknown), (unknown), Ferenc Kiss, (unknown), (unknown), (unknown)	2
4	LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial 2020 ·International Journal of Gynecological Cancer ·Annette Hasenburg, Jalid Sehouli, Bjoern Lampe, Alexander Reuß, (unknown), Antje Belau, (unknown), Sven� Mahner, Peter Hillemanns, Ulrich Petry, Andreas du Bois, Uwe Herwig, Felix Hilpert, Martina Gropp‐Meier, Volker Hanf, Elfriede Greimel, Uwe Wagner, Philipp Harter	5
5	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR) 2016 ·Annals of Oncology ·Jalid Sehouli, Radoslav Chekerov, Alexander Reinthaller, Rolf Richter, Antonio González-Martı́n, Philipp Harter, Hannah Woopen, Edgar Petru, Lars Hanker, (unknown), Pauline Wimberger, Peter Klare, Christian Kurzeder, Felix Hilpert, Antje Belau, Alain G. Zeimet, (unknown), Ulrich Canzler, Sven� Mahner, Werner Meier	24
6	Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology) 2013 ·Cancer Chemotherapy and Pharmacology ·Alexander Mustea, Dominique Koensgen, Antje Belau, Jalid Sehouli, W. Lichtenegger, Laila Schneidewind, H. Sommer, Susanne Markmann, (unknown), (unknown), P. Ledwon, Elena Ioana Braicu, Marek Zygmunt, Gabriele Koehler	13
7	Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer 2013 ·Annals of Oncology ·Bruno V. Sinn, Gϋnter von Minckwitz, Carsten Denkert, Holger Eidtmann, Silvia Darb‐Esfahani, Hans Tesch, Ralf Kronenwett, G. M. Hoffmann, Antje Belau, (unknown), H.-J. Holzhausen, Sven-Thomas Graßhoff, Klaus Baumann, K. Mehta, Manfred Dietel, Sibylle Loibl	30
8	8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy 2012 ·Annals of Oncology ·Bruno V. Sinn, Gϋnter von Minckwitz, Carsten Denkert, Holger Eidtmann, Silvia Darb‐Esfahani, Antje Belau, Ralf Kronenwett, (unknown), K. Mehta, Sibylle Loibl	0
9	Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB–IV 2012 ·Gynecologic Oncology ·Werner Meier, Andreas du Bois, Jörn Rau, Martina Gropp‐Meier, Klaus Baumann, Jens Huober, K. Wollschlaeger, R. Kreienberg, Ulrich Canzler, Barbara Schmalfeldt, Pauline Wimberger, Barbara Richter, W. Schröder, Antje Belau, (unknown), Alexander Burges, Jalid Sehouli	19
10	P1-14-05: Surgical Complications from the GeparQuinto Trial of Patients Receiving Preoperative Bevacizumab. 2011 ·Cancer Research ·Holger Eidtmann, K. Kittel, Mahdi Rezai, Hans Tesch, (unknown), (unknown), Antje Belau, Christine Mau, Elmar Stickeler, Iris Schrader, Peter A. Fasching, (unknown), (unknown), Frank Holms, Kathrin Schwedler, Valentina Nekljudova, Sibylle Loibl, (unknown)	2
11	Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study 2010 ·Breast Cancer Research and Treatment ·Jens Huober, (unknown), Carsten Denkert, Hans Tesch, Erich Weiß, Dirk M. Zahm, Antje Belau, F Khandan, Maik Hauschild, Christoph Thomssen, B. Högel, Silvia Darb‐Esfahani, Keyur Mehta, Sibylle Loibl	220
12	Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study 2007 ·Cancer Chemotherapy and Pharmacology ·Dominique Koensgen, Dirk Stengel, Antje Belau, Peter Klare, Guelten Oskay-Oezcelik, Thomas Steck, Oumar Camara, Alexander Mustea, Harald Sommer, Alexandra Coumbos, Thomas Bogenrieder, W. Lichtenegger, Jalid Sehouli, (unknown)	14
13	5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients 2007 ·European Journal of Cancer Supplements ·Sibylle Loibl, Jacobus Pfisterer, Pauline Wimberger, Christian Kurzeder, Andreas du Bois, (unknown), Antje Belau, Nicole Burchardi, Ignace Vergote, (unknown)	1
14	Toxicity of adjuvant sequential chemo- and radiotherapy of high-risk endometrial carcinoma (HREC)—Results of a phase II multicenter feasibility NOGGO study 2007 ·Journal of Clinical Oncology ·Gabriele Koehler, Jalid Sehouli, H. Sommer, Jens‐Uwe Blohmer, (unknown), Antje Belau	1
15	Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO) 2007 ·Journal of Clinical Oncology ·(unknown), (unknown), Dirk Stengel, Andreas du Bois, Susanne Markmann, S. Loibl, Jochen Wilke, (unknown), Antje Belau, W. Lichtenegger	6
16	Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients 2006 ·Cancer Research ·Jürgen Sonnemann, (unknown), Ralf Ohlinger, Antje Belau, James F. Beck	1
17	The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR 2006 ·Annals of Oncology ·Jacobus Pfisterer, Andreas du Bois, Jalid Sehouli, Sibylle Loibl, Silke Reinartz, Alexander Reuß, Ulrich Canzler, Antje Belau, Christian Jackisch, Rainer Kimmig, K. Wollschlaeger, V. Heilmann, Felix Hilpert	50
18	Selective Pretreatment Diagnostic Imaging for Detecting Remote Metastases in Patients with Endometrial Cancer 2006 ·Oncology Research and Treatment ·(unknown), Ralf Ohlinger, (unknown), Antje Belau, (unknown), Norbert Hosten, Günter Köhler	2
19	Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients 2006 ·BMC Cancer ·Jürgen Sonnemann, (unknown), (unknown), (unknown), Ralf Ohlinger, Antje Belau, Gerd Lorenz, James F. Beck	52
20	A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC–IV (AGO-OVAR protocol OVAR-8) 2004 ·Gynecologic Oncology ·Andreas du Bois, Antje Belau, Uwe Wagner, (unknown), Barbara Schmalfeldt, Barbara Richter, (unknown), Christian Jackisch, Hans-Joachim Lueck, W. Schroeder, Alexander Burges, S. Olbricht, (unknown)	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact